A novel, first in class Notch transcriptional inhibitor, CB-103 has activity on luminal breast cancer stem cells in combination with fulvestrant

Faslodex (fulvestrant) - AstraZeneca

CB-103 - Cellestia Biotech

Majumder S, Crabtree J, Hossain F, Murone M, Lehal R, Miele L LSUHSC, New Orleans; Cellestia Biotech, Lausanne, Switzerland

Dec 3, 2018